Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Prospective Study of Ultrahypofractionated Proton Beam Therapy for Localized Prostate Cancer

9. července 2026 aktualizováno: Sung Uk Lee, National Cancer Center, Korea

Prospective Cohort Study for Identifying Factors Predicting Long-term Outcomes of Prostate Cancer Patients Who Received Ultrahypofractionated Proton Beam Therapy

The goal of this prospective observational cohort study is to evaluate the long-term efficacy and safety of ultrahypofractionated proton beam therapy in patients with localized prostate cancer and to identify clinical and treatment-related factors associated with oncologic outcomes and treatment-related toxicity.

The main questions it aims to answer are:

What are the long-term biochemical recurrence-free survival, clinical progression-free survival, overall survival, and acute and late treatment-related toxicity outcomes following ultrahypofractionated proton beam therapy? Which clinical characteristics, treatment planning parameters, and patient-reported outcomes are predictive of long-term oncologic outcomes and treatment-related toxicity?

Participants will:

Receive protocol-based ultrahypofractionated proton beam therapy (35-40 Gy[RBE] in 5 fractions).

Undergo routine clinical evaluation, laboratory testing including prostate-specific antigen (PSA), and imaging studies according to the institutional follow-up schedule.

Complete patient-reported outcome questionnaires (EPIC-CP and Visual Analog Scale [VAS]) before treatment and during follow-up.

Be followed prospectively to assess biochemical recurrence, clinical progression, survival outcomes, and acute and late treatment-related toxicities.

Přehled studie

Postavení

Nábor

Podmínky

Intervence / Léčba

Detailní popis

Localized prostate cancer can be effectively treated with external beam radiotherapy (EBRT). Ultrahypofractionated radiotherapy has become an established treatment option because of its favorable radiobiological characteristics, shorter treatment duration, and improved patient convenience. Owing to the low alpha/beta ratio of prostate cancer, delivery of larger doses per fraction may provide radiobiological advantages while maintaining excellent tumor control.

Proton beam therapy (PBT) offers unique dosimetric advantages over photon radiotherapy by reducing unnecessary radiation exposure to surrounding normal tissues through the Bragg peak effect. These characteristics may be particularly beneficial for ultrahypofractionated treatment, especially in patients with intermediate- or high-risk disease who require treatment of larger target volumes, including the seminal vesicles or pelvic lymph nodes. However, prospective data regarding the long-term efficacy, safety, patient-reported outcomes, and predictive factors associated with ultrahypofractionated proton beam therapy remain limited.

This is a prospective, single-center observational cohort study conducted at the National Cancer Center, Republic of Korea. Approximately 50 adult patients with histologically confirmed localized prostate adenocarcinoma who are scheduled to undergo definitive ultrahypofractionated proton beam therapy will be prospectively enrolled after providing written informed consent.

All participants will receive protocol-based ultrahypofractionated proton beam therapy consisting of 35-40 Gy(RBE) delivered in five fractions using image-guided proton therapy. Androgen deprivation therapy will be administered according to contemporary clinical guidelines and physician discretion when indicated.

The primary objective of this study is to evaluate the long-term efficacy and safety of ultrahypofractionated proton beam therapy for localized prostate cancer. Secondary objectives include evaluation of biochemical recurrence-free survival, clinical progression-free survival, overall survival, acute and late treatment-related toxicity, and patient-reported quality of life. In addition, the study will prospectively investigate clinical characteristics, treatment planning parameters, dosimetric variables, and patient-reported outcome measures to identify factors associated with oncologic outcomes and treatment-related toxicity.

Clinical information, treatment planning data, physician-reported adverse events, laboratory findings including prostate-specific antigen (PSA), imaging studies, and patient-reported outcome measures using the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) and the Visual Analog Scale (VAS) will be prospectively collected. Patients will be followed every three months during the first two years, every six months during years three and four, and annually thereafter according to institutional follow-up practice.

The findings from this prospective cohort study are expected to provide high-quality evidence regarding the clinical effectiveness and safety of ultrahypofractionated proton beam therapy and to facilitate the development of individualized treatment strategies for patients with localized prostate cancer by identifying predictors of long-term oncologic outcomes and treatment-related toxicity.

Typ studie

Intervenční

Zápis (Odhadovaný)

50

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

  • Jméno: Hyuna Park Clinical Research Coordinator, BS
  • Telefonní číslo: 0491 82-31-920-0491
  • E-mail: 77313@ncc.re.kr

Studijní místa

  • Jižní Korea
    • Gyeonggi-do
      • Goyang-si, Gyeonggi-do, Jižní Korea, 10408
        • Nábor
        • National Cancer Center, Korea
        • Kontakt:

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

  • Dospělý
  • Starší dospělý

Přijímá zdravé dobrovolníky

Ne

Popis

Inclusion Criteria:

  • Histologically confirmed localized adenocarcinoma of the prostate.
  • No evidence of distant metastasis (M0).
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
  • Eligible to receive definitive image-guided ultrahypofractionated pencil beam scanning proton beam therapy according to the study protocol.
  • Ability to complete study questionnaires and comply with scheduled follow-up assessments.
  • Provision of written informed consent before study enrollment.

Exclusion Criteria:

  • Residual or recurrent prostate cancer following prior radical prostatectomy.
  • Previous pelvic radiotherapy.
  • Evidence of distant metastatic disease.
  • Active malignancy within the previous 1 year, except adequately treated basal cell carcinoma or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or completely resected T1N0M0 malignancies.
  • Uncontrolled psychiatric illness, severe traumatic brain injury, chronic alcohol or substance dependence, or other medical conditions that, in the investigator's judgment, would preclude safe participation or adequate follow-up.
  • Inability or unwillingness to provide written informed consent or comply with study procedures.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: N/A
  • Intervenční model: Přiřazení jedné skupiny
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: ultrahypofractionated proton beam therapy
Participants receive definitive ultrahypofractionated proton beam therapy (35-40 Gy[RBE] in 5 fractions) for localized prostate adenocarcinoma using image-guided proton therapy. Participants are prospectively followed for oncologic outcomes, treatment-related toxicity, and patient-reported quality of life.
Záření: Ultrahypofractionated Proton Beam Therapy
Ultrahypofractionated proton beam therapy is delivered using pencil beam scanning (PBS) with image-guided proton therapy. Before treatment planning, all participants undergo placement of an absorbable rectal hydrogel spacer and two intraprostatic gold fiducial markers. Treatment planning is performed using CT simulation with MRI fusion after hydrogel stabilization. Daily cone-beam CT (CBCT) with fiducial marker matching is used for image guidance and patient positioning. A total dose of 36.25-40.0 Gy(RBE) is delivered in 5 fractions over approximately 1-2 weeks. Unlike conventional proton beam therapy using opposed right and left lateral beam arrangements, this protocol employs four oblique beam angles (right anterior oblique, right posterior oblique, left posterior oblique, and left anterior oblique) to optimize dose conformity while minimizing radiation exposure to adjacent normal tissues.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Biochemical recurrence-free survival
Časové okno: Up to 5 years after completion of proton beam therapy
Biochemical recurrence is defined according to the Phoenix definition (PSA nadir + 2 ng/mL). Biochemical recurrence-free survival is measured from completion of proton beam therapy to biochemical recurrence or last follow-up.
Up to 5 years after completion of proton beam therapy

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Patient-reported quality of life
Časové okno: baseline, postRT 1 month, 4 months, 7 months and 1 year
Patient-reported quality of life will be assessed using the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP). Scores range from 0 to 100, with higher scores indicating better urinary quality of life.
baseline, postRT 1 month, 4 months, 7 months and 1 year
Clinical recurrence-free survival
Časové okno: Up to 5 years after completion of proton beam therapy
Time from radiotherapy completion to first occurrence of any clinical recurrence (local, regional, or distant) or death. Recurrence will be confirmed by imaging studies and/or histopathological findings when available.
Up to 5 years after completion of proton beam therapy
Overall survival
Časové okno: From completion of proton beam therapy to 5 years after treatment
Time from completion of ultrahypofractionated proton beam therapy to death from any cause. Participants who are alive at the time of analysis will be censored at the date of the last follow-up.
From completion of proton beam therapy to 5 years after treatment
Treatment-related genitourinary toxicity
Časové okno: Up to 5 years after completion of proton beam therapy
Treatment-related genitourinary (GU) toxicity will be assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Acute toxicity is defined as adverse events occurring within 90 days after completion of proton beam therapy, and late toxicity as events occurring more than 90 days after treatment completion.
Up to 5 years after completion of proton beam therapy
Treatment-related gastrointestinal toxicity
Časové okno: Up to 5 years after completion of proton beam therapy
Treatment-related gastrointestinal (GI) toxicity will be assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Acute toxicity is defined as adverse events occurring within 90 days after completion of proton beam therapy, and late toxicity as events occurring more than 90 days after treatment completion.
Up to 5 years after completion of proton beam therapy

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

National Cancer Center, Korea

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

4. listopadu 2024

Primární dokončení (Odhadovaný)

31. prosince 2034

Dokončení studie (Odhadovaný)

31. prosince 2034

Termíny zápisu do studia

První předloženo

2. července 2026

První předloženo, které splnilo kritéria kontroly kvality

9. července 2026

První zveřejněno (Aktuální)

13. července 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

13. července 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

9. července 2026

Naposledy ověřeno

1. července 2026

Více informací

Termíny související s touto studií

Klíčová slova

Další relevantní podmínky MeSH

Další identifikační čísla studie

  • NCC2024-0253

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

produkt vyrobený a vyvážený z USA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Klinické studie na Novotvar prostaty

Klinické studie na Ultrahypofractionated Proton Beam Therapy

Prohledejte podobné pokusy

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

CROs by country

CROs in Zambia

Podmínky

Vzácné nemoci

Drogové intervence

Doplňky stravy

Sponzor / Spolupracovníci

Místa

Předplatit